Overview
RxHCC is the prescription-drug analog to the CMS-HCC model. Where CMS-HCC adjusts Medicare Advantage Part C payments for medical-cost variation, RxHCC adjusts Part D prescription drug plan payments for variation in expected drug spending. The two models share a diagnosis-to-category mapping architecture but produce distinct risk scores with different coefficients; a member's medical RAF and Rx risk score are independent numbers.
The RxHCC model includes approximately 80 condition categories calibrated to Part D spending patterns. Categories that strongly predict prescription cost — diabetes with complications, rheumatoid arthritis, HIV, multiple sclerosis, cystic fibrosis, transplant status, and several cancer categories — carry substantially higher coefficients than they do in the medical model. Conversely some medically expensive conditions (certain surgical histories, acute injuries) carry lower Rx coefficients because they are less predictive of ongoing drug spend.
Part D plans use RxHCC scores to price bids, set formulary tiers, and reconcile payments with CMS. Because Part D operates on a separate payment stream from Part C, plans that also offer Medicare Advantage Prescription Drug (MAPD) plans must maintain both CMS-HCC and RxHCC accuracy simultaneously. An MA-PD member's chart review therefore typically targets both risk-adjustment models — a single chart validation effort can support recapture in both.
Payment-year mechanics mirror the medical model. RxHCC uses diagnoses from the prior calendar year to set prospective payments for the current year, with mid-year reconciliation and final reconciliation after CMS reviews encounter submissions. The Encounter Data Processing System (EDPS) is the submission pathway. Submission deadlines and reopening windows track the medical model, so risk-adjustment teams generally align processes rather than maintain parallel workflows.
RADV audits apply to RxHCC as well as CMS-HCC. The auditor samples member charts and validates that every diagnosis reported against an RxHCC maps to MEAT-compliant documentation. Unsupported RxHCCs are recouped with extrapolation; the 2023 RADV final rule explicitly includes extrapolation for both models with no separate error-rate offset.
Operationally, providers rarely interact with RxHCC directly — it is primarily a plan-side payment mechanic. But provider organizations participating in MA-PD shared-risk arrangements should understand the model because coding practices that improve CMS-HCC capture generally improve RxHCC capture as well, and because some ACO REACH and MSSP enhanced-track benchmarks include Part D spending components that are themselves RxHCC-adjusted.
The model is recalibrated periodically by CMS. The 2024 recalibration modestly shifted coefficients for diabetes subtypes and added finer gradation in the chronic-pain category; the 2025 update further refined HIV and oncology coefficients.
Industry benchmark
Medicare Part D RxHCC risk scores average ~1.00 across the enrolled population by design. Plans serving chronically ill populations typically see Rx scores of 1.2–1.5; low-utilization populations run 0.7–0.9.
Worked example
An MA-PD plan has 80,000 members. Post-chart-review, the team recaptures 3,200 diabetes-with-complications diagnoses also predictive in the RxHCC model. Average Rx risk increases by 0.04, lifting the per-member Part D direct subsidy by about $85 annually — roughly $6.8M of incremental Part D revenue for the plan year on top of the Part C CMS-HCC revenue gain from the same recapture effort.
Frequently asked questions — RxHCC (Prescription Drug Hierarchical Condition Category)
Is RxHCC the same as CMS-HCC?
No. Both are CMS risk-adjustment models, but RxHCC sets Part D drug plan payments while CMS-HCC sets Part C medical payments. They share diagnosis-mapping architecture but have different coefficients and category structures.
Do providers need to code for RxHCC specifically?
No separate coding — RxHCC uses the same ICD-10-CM diagnoses as CMS-HCC. But providers participating in MA-PD risk-sharing should confirm the ICD-10-CM codes they submit capture conditions predictive of drug spend, not just medical spend.
How often is the RxHCC model recalibrated?
Every few years via CMS Notice of Proposed Rulemaking and Final Rule cycles. Recent updates (2024, 2025) refined coefficients for diabetes, HIV, and oncology. Plans model bid impact each cycle.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.